Conexeu Sciences Inc. (Nasdaq: CNXU) · social, search & AEO plan · 2026-08-20
Conexeu has the only story in aesthetics that needs a cross-section to tell.
It is currently telling that story to 746 people on LinkedIn and 695 on Instagram, in a category where the single best-performing brand post anyone has published is an animated journey under the skin. That is not a content problem. It is an unclaimed lane.
The thesis
Everyone in this category sells a result. Conexeu is the only one that can sell a mechanism.
Aesthetics social media is a saturated market for one specific claim: look better afterwards. Every filler, toxin and biostimulator brand competes on the same axis with the same assets — a face, a needle, a before and an after. CXU™ cannot compete on that axis. It is a device candidate in preclinical development, so results are off the table by law.
That constraint is the opportunity. The one axis Conexeu is free to own outright is the axis the category has abandoned: what actually happens under the skin, and why architecture is a different job from volume. When we read the live feeds, the highest-performing brand-owned post in the entire aesthetics injectable field was not a face. It was an animated cross-section.
The best post in the category is a diagram in motion — and Conexeu is the only company here whose product is the diagram.
Galderma’s “let’s go deep” reel — a camera move through epidermis, dermis and hypodermis — pulled 4,337 engagements on a 76.4k account: 56.8 per thousand followers. The next-best brand-owned post we read on Instagram managed 12.1 per thousand. A brand asking practitioners to “share the legacy with your patients” managed 2.0.
A 28× spread between two posts on the same platform, in the same category, in the same year, is not noise. It is the category telling us what it wants and not being listened to.
56.8
Engagements per 1,000 followers
Galderma’s sub-dermal mechanism reel. The category ceiling we found.
2.0
Same brand tier, trade copy
Merz asking injectors to pass the brand on. Same platform, 28× less pull.
746
People who see Conexeu on LinkedIn
Galderma’s corporate page carries 558,848. Integra carries 100,252.
0
Brand-owned TikTok accounts in the category
Not Galderma, not Merz, not Renuva. A regulatory judgment, not an oversight — Chapter 06 prices it.
Every figure on this page was read off the live post or profile on 2026-08-20. Engagement counts move; the ratios between them have been stable across the read set.
How to read this
Nine chapters, in the order the argument has to be made
This is a plan, not a survey. Each chapter answers one question and hands the next chapter its premise.
01 · Where we stand
The live audit. Every Conexeu post, its real engagement, the cadence gaps, and the three site defects that waste the traffic social sends.
02 · The five post types
The formats that actually earn distribution, ranked, with the specs to build them and the compliance rail on each one.
03 · What wins in the category
Twenty posts read off the live feeds in life sciences and aesthetics, sortable, with the pattern that falls out of them.
04 · The competitor board
Three rings of competitor — structural analogs, category owners, regeneration-narrative peers — and their best work.
05 · The gap and the steal
Six plays where the lane is measurably empty, with the evidence that it is empty and how the win gets counted.
06 · Channel by channel
Instagram, LinkedIn, TikTok, Facebook. Role, cadence, specs, and what never to post there.
07 · Social SEO and AEO
How these posts get found in Google and quoted inside AI answers — and the entity-graph work that is currently blocking both.
08 · The 90-day build
Four phases, named owners, and the assets that already exist in the vault.
The constraint that shapes every page
CXU™ is a device candidate in preclinical development and is not cleared or approved for marketing in any jurisdiction. FDA treats virtually any public statement implying an investigational device is safe or can treat a condition as unlawful promotion.
So: no results, no patient stories, no before-and-afters, no efficacy verbs. Every recommendation in this document has been written inside that fence, and the fence is drawn explicitly on each post type in Chapter 02.